Actinic Keratoses: A Prospective Pilot Study on a Novel Formulation of 4% 5-Fluorouracil Cream and a Review of Other Current Topical Treatment Options.
5-Fluorouracil
actinic keratosis
dermoscopy
non-melanoma skin cancer
skin cancer
therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 May 2023
28 May 2023
Historique:
received:
11
02
2023
revised:
13
04
2023
accepted:
25
05
2023
medline:
10
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
Actinic keratosis (AK) is one of the most common skin diseases, with a low risk of progression into invasive squamous cell carcinoma. We aim to assess efficacy and safety of a novel formulation of 5-Fluorouracil (5-FU) 4% with once daily application for the treatment of multiple AKs. A pilot study was performed on 30 patients with a clinical and dermoscopic diagnosis of multiple AKs, enrolled between September 2021 and May 2022 at the Dermatology Departments of two Italian hospitals. Patients were treated with 5-FU 4% cream once daily for 30 consecutive days. The Actinic Keratosis Area and Severity Index (AKASI) was calculated before starting therapy, and at each follow-up, to assess objective clinical response. The cohort analyzed included 14 (47%) males and 16 (53%) females (mean age: 71 ± 12 years). A significant decrease in AKASI score at both 6 and 12 weeks ( In the setting of topical chemotherapy and immunotherapy, the new formulation of 5-FU 4% proved to be a highly effective treatment for AKs and field cancerization.
Sections du résumé
BACKGROUND
BACKGROUND
Actinic keratosis (AK) is one of the most common skin diseases, with a low risk of progression into invasive squamous cell carcinoma. We aim to assess efficacy and safety of a novel formulation of 5-Fluorouracil (5-FU) 4% with once daily application for the treatment of multiple AKs.
METHODS
METHODS
A pilot study was performed on 30 patients with a clinical and dermoscopic diagnosis of multiple AKs, enrolled between September 2021 and May 2022 at the Dermatology Departments of two Italian hospitals. Patients were treated with 5-FU 4% cream once daily for 30 consecutive days. The Actinic Keratosis Area and Severity Index (AKASI) was calculated before starting therapy, and at each follow-up, to assess objective clinical response.
RESULTS
RESULTS
The cohort analyzed included 14 (47%) males and 16 (53%) females (mean age: 71 ± 12 years). A significant decrease in AKASI score at both 6 and 12 weeks (
CONCLUSIONS
CONCLUSIONS
In the setting of topical chemotherapy and immunotherapy, the new formulation of 5-FU 4% proved to be a highly effective treatment for AKs and field cancerization.
Identifiants
pubmed: 37296918
pii: cancers15112956
doi: 10.3390/cancers15112956
pmc: PMC10251935
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Dermatolog Treat. 2010 Sep;21(5):267-71
pubmed: 19878034
JAMA Dermatol. 2018 Feb 1;154(2):167-174
pubmed: 29299592
Clin Exp Dermatol. 2012 Jul;37(5):567-9
pubmed: 22300301
J Dermatolog Treat. 2017 Aug;28(5):431-442
pubmed: 27796187
J Dermatolog Treat. 2022 Aug;33(5):2664-2669
pubmed: 35435128
Arch Immunol Ther Exp (Warsz). 2021 Feb 27;69(1):3
pubmed: 33638703
Curr Probl Dermatol. 2015;46:70-6
pubmed: 25561209
Br J Dermatol. 2018 Sep;179(3):763-764
pubmed: 29572818
Int J Dermatol. 1998 Sep;37(9):677-81
pubmed: 9762818
Dermatol Ther. 2020 Jul;33(4):e13744
pubmed: 32478958
Clin Dermatol. 2014 Jan-Feb;32(1):80-7
pubmed: 24314380
J Dermatolog Treat. 2020 Sep;31(6):576-582
pubmed: 31625770
JCI Insight. 2019 Mar 21;4(6):
pubmed: 30895944
Expert Rev Anticancer Ther. 2013 May;13(5):541-58
pubmed: 23617346
Br J Dermatol. 2011 Nov;165(5):1101-8
pubmed: 21517801
Int Immunopharmacol. 2013 Oct;17(2):427-31
pubmed: 23867290
Dermatol Ther (Heidelb). 2022 Feb;12(2):467-479
pubmed: 34954811
Dermatol Ther. 2021 Mar;34(2):e14846
pubmed: 33528869
Mol Cell Biol. 1995 Apr;15(4):2207-18
pubmed: 7534379
Am J Clin Dermatol. 2022 May;23(3):339-352
pubmed: 35182332
J Dermatol. 2014 Jun;41(6):487-93
pubmed: 25032251
Clin Ther. 2002 Jun;24(6):990-1000
pubmed: 12117087
J Drugs Dermatol. 2016 Oct 1;15(10):1218-1224
pubmed: 27741339
Int J Dermatol. 2016 Aug;55(8):831-44
pubmed: 27387373
Arch Dermatol. 2012 Oct;148(10):1159-64
pubmed: 23069952
Drugs Aging. 2022 Feb;39(2):143-152
pubmed: 35156172
J Eur Acad Dermatol Venereol. 2015 May;29(5):991-7
pubmed: 25428612
J Eur Acad Dermatol Venereol. 2018 May;32(5):752-756
pubmed: 29117441
J Clin Invest. 2017 Jan 3;127(1):106-116
pubmed: 27869649
J Dermatolog Treat. 2020 May;31(3):285-289
pubmed: 30836026
N Engl J Med. 2019 Mar 7;380(10):935-946
pubmed: 30855743
Dermatol Pract Concept. 2022 Jan 01;12(1):e2022031
pubmed: 35223175
J Am Acad Dermatol. 1991 May;24(5 Pt 1):738-43
pubmed: 1869646
Int J Dermatol. 2019 Apr;58(4):400-407
pubmed: 30070357
J Leukoc Biol. 1994 Feb;55(2):234-40
pubmed: 7507969
Int J Dermatol. 2020 Jun;59(6):677-684
pubmed: 32012240
Curr Med Chem. 2007;14(6):681-7
pubmed: 17346155